The evolving landscape of tissue‐agnostic therapies in precision oncology

Vivek Subbiah(Sarah Cannon), Razelle Kurzrock(Medical College of Wisconsin), Bettina Ryll(Stockholm School of Economics), Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Howard A. Burris(Deaconess Hospital)

CA A Cancer Journal for Clinicians

May 30, 2024

10.3322/caac.21844

Cited by 68

Related Papers

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

|Journal of Clinical Oncology|1997|5.9k

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

|The Lancet|2016|3.7k

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

|Nature|2014|2.4k

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

|Molecular Cancer Therapeutics|2017|2.4k

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

|Molecular Cancer Therapeutics|2015|2.3k